Amgen Lobs Patent Suit At Sandoz's Neulasta Biosimilar
Amgen Inc. sued Sandoz Inc. in California federal court on Thursday for allegedly infringing two patents related to anti-infection biologic Neulasta when developing a biosimilar version of the blockbuster product....To view the full article, register now.
Already a subscriber? Click here to view full article